Common Contracts
1 similar null contracts
Grant Agreement no: 260576June 28th, 2016
Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders in children, affecting approximately 5% of children in Europe. Methylphenidate (MPH), a central nervous system stimulant, is the most commonly prescribed medication for children suffering from ADHD; it is also increasingly used to treat ADHD in adults. In 2007 the European Commission requested a referral to the Committee for Medicinal Products for Human Use (CHMP) under Article 31 of Directive 2001/83/EC, as amended, for MPH because of possible safety concerns. The CHMP concluded that a study of the long term effects of MPH on growth, sexual development, neurological system, psychiatric states and cardiovascular system was needed. In response to the concerns of the CHMP, the ADDUCE (Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects) research team was formed by a consortium of experts in the fields of ADHD, drug safety, neuropsychopharmacology and cardiovascular resear
